Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.39 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30411163 | 1.00 | LMNA (0.45) | LMNASMN1; SMN2NCOA3KMT2AL3MBTL1 | |
| SCHEMBL23991581 | 0.91 | SMN1; SMN2 (0.56) | LMNASMN1; SMN2KMT2AL3MBTL1POLB | |
| SCHEMBL30410698 | 0.91 | SMN1; SMN2 (0.56) | LMNASMN1; SMN2KMT2AL3MBTL1POLB | |
| SCHEMBL30411887 | 0.87 | SMN1; SMN2 (0.41) | LMNASMN1; SMN2KMT2AL3MBTL1MAPT | |
| SCHEMBL23991450 | 0.87 | SMN1; SMN2 (0.41) | LMNASMN1; SMN2KMT2AL3MBTL1MAPT | |
| SCHEMBL25312800 | 0.86 | NCOA3 (0.48) | LMNASMN1; SMN2NCOA3KMT2AL3MBTL1 | |
| SCHEMBL30411145 | 0.85 | SMN1; SMN2 (0.43) | LMNASMN1; SMN2KMT2AL3MBTL1MAPT | |
| SCHEMBL23991589 | 0.85 | SMN1; SMN2 (0.43) | LMNASMN1; SMN2KMT2AL3MBTL1MAPT | |
| SCHEMBL23991396 | 0.84 | SYK (0.37) | LMNASMN1; SMN2NPSR1HPGD | |
| SCHEMBL30410692 | 0.84 | SYK (0.37) | LMNASMN1; SMN2NPSR1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559502-B2 | Thieno pyrimidines as ferroportin inhibitors | Global Blood Therapeutics, Inc (US) | 2026-02-24 | — | — | US | disclosed |
| US-20230159553-A1 | THIENO PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230159553-A1 | THIENO PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2023-05-25 | — | — | US | disclosed |
| EP-4143197-A1 | THIENO PYRIMIDINES AS FERROPORTIN INHIBITORS | Global Blood Therapeutics, Inc. (US) | 2023-03-08 | — | — | EP | disclosed |
| WO-2021222359-A1 | THIENO PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| WO-2021222359-A1 | THIENO PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159553-A1 | THIENO PYRIMIDINES AS FERROPORTIN INHIBITORS | SLC40A1, HAMP, SLC19A1 | LMNA 2258/4885SMN1; SMN2 2084/4885NCOA3 2360/4885 |
| US-12559502-B2 | Thieno pyrimidines as ferroportin inhibitors | HAMP, TFRC, SLC40A1 | LMNA 1020/4885SMN1; SMN2 1963/4885NCOA3 483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.